Wegovy vs. semaglutide: is there a difference between them?

Wegovy vs. semaglutide can be a common question in the world of weight loss. The two names are often used interchangeably, but they don’t mean the same thing. If you're exploring your weight loss options, knowing the difference can change which treatment makes sense for you.

Wegovy is a brand-name medication. Its active ingredient is semaglutide. Think of it like Advil and ibuprofen: They share the same active compound; they just have different names on the box. 

So, Wegovy is semaglutide, but not all semaglutide is Wegovy.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. In plain terms, it mimics a hormone your body naturally releases after eating — one that signals fullness, slows digestion, and helps regulate blood sugar.

The US Food and Drug Administration (FDA) has approved semaglutide under several brand names: Wegovy, Ozempic, and Rybelsus. Each has its own approved uses, doses, and available forms.

Wegovy comes as a weekly injection and a daily oral tablet (Wegovy pill). Both forms are approved for weight loss and management and cardiovascular risk reduction. The Wegovy injection is also approved for the treatment of fatty liver disease. 

In addition to Wegovy, semaglutide is also available as an injection (Ozempic) and a daily oral pill (Ozempic pill, Rybelsus)*. Both forms are approved for type 2 diabetes and for cardiovascular risk reduction. The Ozempic injection is also indicated for reducing the risk of kidney decline and death associated with kidney disease. 

*As of May 2026, Rybelsus is being phased out and transitioning fully to the Ozempic pill. People may still be prescribed Rybelsus (3 mg, 7 mg, 14 mg) until the remaining supply is depleted.

See if you qualify

The main difference between Wegovy and other semaglutide products comes down to dose and what each one is approved to treat.

Wegovy comes in two forms, each with its own maintenance dose: a 2.4 mg weekly injection or a 25 mg daily pill.

Ozempic is available in doses of up to 2 mg weekly as an injection or up to 9 mg daily as a pill.

Rybelsus, the original oral semaglutide, starts at 3 mg and goes up to 14 mg, though it's gradually being replaced by the Ozempic pill in the US.

The oral doses are higher than the injectable ones because the body absorbs oral semaglutide less efficiently through the gut than through injections.

Adults with obesity using 2.4 mg semaglutide weekly alongside lifestyle changes lost an average of 14.9% of their body weight over 68 weeks, with 86% losing at least 5%.

That evidence is specific to Wegovy's 2.4 mg dose. Ozempic uses a lower dose approved for diabetes, and while some people do lose weight on it, that's not what it was designed or studied for.

Since all semaglutide products share the same active compound, their side effect profiles are similar.

The most common complaints are digestive: nausea, vomiting, diarrhea, constipation, and stomach discomfort.

They hit hardest at the start of treatment or after a dose increase, with around 74% of semaglutide users reporting gastrointestinal (GI) side effects compared to 48% in placebo groups. For most people, symptoms settle down and disappear as their body adjusts.

On the more serious end, pancreatitis, gallbladder problems, and kidney issues have been reported, though these are less common.

All semaglutide products also carry a boxed warning about a potential risk of thyroid tumors, based on animal studies. It isn't yet known whether that risk applies to humans.

Before starting any semaglutide drug, it's worth going through your full medical history with a healthcare provider. Dosage and treatment decisions should always be made with your provider, not on your own.

You may notice your blood sugar improves as you lose weight on Wegovy. That typically happens along with weight loss, though it’s not what the brand-name medication is specifically approved for.

In one trial, people with type 2 diabetes on the same dose used in Wegovysaw their blood sugar levels drop by 1.6 percentage points over 68 weeks, compared with a much smaller drop on placebo.

Ozempic and Rybelsus are different. Both are approved specifically to help people with type 2 diabetes control their blood sugar.

People on the higher 2 mg dose of Ozempic saw their blood sugar levelsdrop by 2.2 percentage points after 40 weeks, compared with a smaller drop (1.9 percentage points) on the 1 mg dose.

Rybelsus showed asmaller but still meaningful improvement over six months at its highest dose.

So if blood sugar is the main concern, Ozempic and Rybelsus are the medications designed for that. Wegovy was never studied for it, and isn't meant to be used that way.

Heart disease isone of the leading causes of death for people with diabetes, which makes cardiovascular protection a major factor for a lot of people choosing between these medications.

Adults with obesity or overweight who already had heart disease and took Wegovylowered their risk of a heart attack, stroke, or cardiovascular death by 20% compared with those on a placebo.

Rybelsus has similar backing: people with type 2 diabetes taking the oral form of semaglutidecut that same risk by 14% over four years compared with placebo.

Ozempic injections carry the same cardiovascular approval, based on earlier trial results in people with type 2 diabetes and heart disease.

So, depending on the form someone is prescribed, cardiovascular protection may come bundled in with the primary reason they're taking it, whether that's weight loss or blood sugar control.

Wegovy is currently the only semaglutide product approved to treat MASH, a serious liver condition. Neither Ozempic nor Rybelsus is approved for it.

MASH develops when fat builds up in the liver and triggers inflammation and scarring (fibrosis) that can progress to liver failure over time. It tends to be more common in people with obesity, type 2 diabetes, or high cholesterol.

The ESSENCE trial followed nearly 1,200 adults with biopsy-confirmed MASH. After 72 weeks, 62.9% of those on 2.4 mg weekly semaglutide saw their liver inflammation (steatohepatitis) resolve without their scarring getting worse, compared with 34.3% on placebo.

This approval applies to the Wegovy injection specifically, not the pill or the diabetes-focused semaglutide brands.

Check your coverage for FDA-approved GLP-1s—for free

Check for free

None of these medications work overnight. Each one follows a slow dose increase schedule, and results build up over months rather than weeks.

People using the original Wegovy injectionlost close to 15% of their body weight over 68 weeks.

The newer Wegovy pill follows a similar pace, with people in its main triallosing roughly 14% of their body weight by week 64.

Blood sugar improvements with Ozempic can begin within the first several weeks of treatment, sincethe medication reaches steady levels in the body in about a month, though clinical trials typically measure and report results starting around 30 weeks.

Because the effects build up gradually, patience plays a bigger role here than with a lot of medications. The dosing schedules themselves take three to four months to complete before reaching a stable maintenance dose, so you may not have a clear sense of whether a medication is working until then.

Semaglutide leaves the body slowly. After a final dose, it takes about five weeks for the medication to clear out completely, whether it was taken as Wegovy, Ozempic, or Rybelsus. The body clears it a bit at a time: Roughly half of a dose is gone after a week (sometimes called the drug's half-life), and it takes several more weeks for the rest to work its way out.

This slow exit is part of why the injection only needs to be taken once a week instead of every day. It also means that when someone stops treatment, the effects, including reduced appetite and any side effects, ease off gradually rather than all at once.

Compounded semaglutide is a customized version of semaglutide that’s tailored to meet the needs of an individual patient or a copy version to help meet supply needs during a shortage. 

Unlike Wegovy, compounded semaglutide is not FDA-approved and therefore does not undergo FDA review for safety, effectiveness, or manufacturing. So, if your healthcare provider recommends compounded semaglutide, it’s important to ensure you purchase it from a licensed compounding pharmacy that complies with federal and state laws. Wegovy, for comparison, is produced and manufactured only by Novo Nordisk. 

Speaking of which, Novo Nordisk currently holds the patents for semaglutide, including brand-name Wegovy. Until this patent expires — which isn’t until 2041, at the earliest — there is no true generic Wegovy or any brand-less semaglutide medication in the US. 

Wegovy and semaglutide are closely related but not the same. Wegovy is the brand name, and semaglutide is the active ingredient.

• When it comes to Wegovy vs. semaglutide, it’s important to note that only one version is approved for weight loss. Wegovy is the only semaglutide brand FDA-approved for weight management, while the others (Ozempic, Rybelsus) are primarily diabetes medications.

• Doses vary across semaglutide drugs, including Wegovy. Wegovy’s weight-loss doses — 2.4 mg weekly as an injection or 25 mg daily as a pill — run higher than the doses used in the Ozempic pen, Ozempic pill, and Rybelsus.

• All semaglutide products share the same active ingredient, so their side effect profiles line up closely. GI symptoms tend to be the most common, particularly early in treatment.

What's right for you depends on your health history, your goals, and your circumstances. On Ro, you can connect with a licensed healthcare provider who can help you work through your options and find the most suitable path forward.